Inflammaging and Musculoskeletal Health: Mechanisms, Clinical Impact, and Emerging Therapeutic Strategies

Abstract

Inflammaging, defined as the age-associated chronic, low-grade inflammation, has emerged as a critical factor influencing musculoskeletal health. This review articulates the epidemiology, mechanistic insights, clinical manifestations, diagnostic approaches, and management strategies for inflammaging in the context of musculoskeletal disorders. Recent scientific advances and guideline-based recommendations are highlighted to inform clinical practice and research directions.

Introduction

The concept of inflammaging has revolutionized our understanding of the interplay between aging and chronic inflammatory states, particularly in relation to musculoskeletal health. Characterized by persistent, subclinical elevations in pro-inflammatory cytokines, inflammaging accelerates tissue degeneration, impairs repair mechanisms, and predisposes elderly individuals to a spectrum of musculoskeletal conditions, including osteoarthritis, sarcopenia, osteoporosis, and frailty syndromes. Given the growing aging population worldwide, elucidating the impact of inflammaging on musculoskeletal health is paramount for clinicians and researchers alike.

Epidemiology / Disease Burden

Population-based studies indicate that musculoskeletal diseases attributable to inflammaging are highly prevalent among individuals aged 65 years and older. Osteoarthritis affects over 30% of this demographic, while sarcopenia and osteoporosis collectively account for a significant proportion of disability-adjusted life years (DALYs) in the elderly. The economic burden is substantial, with direct and indirect healthcare costs escalating in tandem with the global rise in life expectancy. Inflammaging is increasingly recognized as a key driver of this burden, amplifying the risk and severity of musculoskeletal pathologies as part of the aging process.

Pathophysiology

At the cellular and molecular levels, inflammaging is orchestrated by dysregulated innate immunity, mitochondrial dysfunction, and impaired autophagy. Chronic exposure to senescence-associated secretory phenotype (SASP) factors such as interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-α), and C-reactive protein (CRP) infiltrates musculoskeletal tissues, leading to extracellular matrix degradation, myocyte apoptosis, and osteoclast activation. These processes culminate in cartilage loss, bone resorption, and muscle wasting. Recent evidence implicates the NLRP3 inflammasome and altered gut microbiota as upstream modulators, while systemic metabolic changes, such as insulin resistance and adipokine dysregulation, further exacerbate tissue vulnerability to age-related degeneration.

Risk Factors

Intrinsic factors contributing to inflammaging include genetic predisposition, mitochondrial DNA mutations, and an age-related decline in immune surveillance. Extrinsic risk modifiers encompass lifestyle factors such as poor nutrition, physical inactivity, obesity, chronic infections, and environmental exposures. Notably, the presence of comorbidities diabetes, cardiovascular disease, and chronic kidney diseas potentiates the pro-inflammatory milieu, heightening susceptibility to musculoskeletal impairment. Polypharmacy and persistent psychosocial stress have also been identified as amplifiers of systemic inflammation in elderly populations.

Clinical Features

Clinically, inflammaging manifests as progressive joint pain, stiffness, decreased mobility, muscle weakness, and heightened fracture risk. Patients often exhibit overlapping features of osteoarthritis (joint swelling, crepitus), sarcopenia (loss of muscle mass and strength), and osteoporosis (height loss, vertebral deformities). Subtle symptoms such as fatigue and low-grade fever may accompany more advanced disease. Importantly, these features evolve insidiously, often leading to under-recognition and delayed intervention, which can precipitate irreversible functional decline.

Diagnosis

Diagnostic evaluation relies on a combination of clinical assessment, laboratory biomarkers, and imaging studies. Elevated serum levels of IL-6, TNF-α, CRP, and ferritin are indicative of chronic inflammation. Dual-energy X-ray absorptiometry (DEXA) and quantitative MRI provide quantitative insights into bone and muscle integrity. Emerging modalities, including PET-MRI targeting inflammatory cell infiltration and circulating microRNA profiles, offer promise for early detection and risk stratification. Diagnostic criteria for sarcopenia (EWGSOP2) and osteoarthritis (ACR/EULAR) now incorporate inflammatory biomarkers, reflecting the central role of inflammaging.

Treatment & Management

Management strategies are multifaceted, targeting both inflammatory pathways and musculoskeletal preservation. Non-pharmacological interventions regular resistance exercise, Mediterranean diet, weight optimization, and smoking cessation are foundational. Pharmacotherapies include NSAIDs for symptomatic relief, disease-modifying agents (such as bisphosphonates and selective estrogen receptor modulators), and biologics targeting IL-6 or TNF-α in refractory cases. Vitamin D and calcium supplementation are recommended for bone health. Multidisciplinary rehabilitation and fall prevention programs are integral to optimizing functional outcomes.

Recent Advances / Emerging Therapies

Recent research has elucidated novel therapeutic targets, including senolytics, NLRP3 inflammasome inhibitors, and gut microbiota modulation. Early-phase clinical trials of senolytic drugs (e.g., dasatinib and quercetin) demonstrate potential in reducing SASP burden and improving musculoskeletal function in elderly cohorts. Probiotic and prebiotic interventions are under investigation for their capacity to restore gut barrier integrity and attenuate systemic inflammation. Advances in regenerative medicine, such as mesenchymal stem cell therapy and tissue engineering, are being explored for cartilage and muscle repair in the context of inflammaging.

Guideline Recommendations

International consensus guidelines (ESCEO, EULAR, EWGSOP2) advocate for early risk assessment and individualized intervention strategies combining lifestyle modification, pharmacotherapy, and rehabilitation. Regular monitoring of inflammatory biomarkers and functional status is recommended for high-risk older adults. Multimodal approaches integrating geriatric assessment, nutritional support, and patient-centered care pathways are endorsed to mitigate the impact of inflammaging on musculoskeletal health.

Conclusion

Inflammaging represents a pivotal mechanism underpinning the pathogenesis of age-related musculoskeletal disorders. A comprehensive approach encompassing early identification, mechanistic understanding, and evidence-based management is essential to address the growing clinical and societal burden. Ongoing research into novel therapeutics and biomarker-driven strategies holds promise for improving outcomes and preserving musculoskeletal health in the aging population.